Comparative Pharmacology
Head-to-head clinical analysis: IV PERSANTINE versus NIPRIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IV PERSANTINE versus NIPRIDE.
IV PERSANTINE vs NIPRIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits adenosine deaminase and phosphodiesterase, increasing intracellular cAMP and adenosine; causes coronary vasodilation and inhibits platelet aggregation.
Nipride (sodium nitroprusside) is a potent vasodilator that acts directly on vascular smooth muscle, both arterial and venous, by releasing nitric oxide (NO). Nitric oxide activates guanylate cyclase, increasing cyclic GMP levels, leading to relaxation of smooth muscle and subsequent reduction in peripheral vascular resistance and blood pressure.
0.14 mg/kg/min intravenous infusion over 4 minutes for myocardial perfusion imaging.
Intravenous infusion: initial 0.3-0.5 mcg/kg/min, titrate up to 10 mcg/kg/min as needed.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours in adults; may be prolonged in patients with hepatic impairment.
Nitroprusside: ~2 minutes (converted to cyanide); cyanide (as thiocyanate): 2.7 days; clinical context: continuous IV infusion required; thiocyanate accumulation risk in renal impairment.
Primarily hepatic metabolism (glucuronidation) with enterohepatic recirculation; renal excretion of unchanged drug is minimal (<1%); biliary/fecal elimination accounts for approximately 90% of the dose.
Renal: ~50% as unchanged drug; hepatic metabolism to thiocyanate, which is renally eliminated (half-life 2-3 days); <1% fecal.
Category C
Category C
Vasodilator
Vasodilator